In Re Cardizem CD Antitrust Litigation

90 F. Supp. 2d 819, 90 F. Supp. 819, 1999 U.S. Dist. LEXIS 20698, 1999 WL 1569794
CourtDistrict Court, E.D. Michigan
DecidedOctober 15, 1999
Docket99-md-1278, MDL No. 1278
StatusPublished
Cited by26 cases

This text of 90 F. Supp. 2d 819 (In Re Cardizem CD Antitrust Litigation) is published on Counsel Stack Legal Research, covering District Court, E.D. Michigan primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
In Re Cardizem CD Antitrust Litigation, 90 F. Supp. 2d 819, 90 F. Supp. 819, 1999 U.S. Dist. LEXIS 20698, 1999 WL 1569794 (E.D. Mich. 1999).

Opinion

MEMORANDUM OPINION AND ORDER DENYING IN PART AND GRANTING IN PART PLAINTIFFS’ MOTIONS FOR REMAND

EDMUNDS, District Judge.

Plaintiffs in these consolidated cases brought class-action suits in state court against Defendants Hoechst Aktiengesells-chaft, Hoechst Marion Roussel, Inc. (“Hoechst”), and Andrx Pharmaceuticals, Inc. (“Andrx”) alleging that Defendants have violated various state antitrust and related laws, have conspired and entered into arrangements that' have effectively prevented any lower-cost generic version of a prescription heart medication, known as Cardizem CD, from entering the United States marketplace, and have thus harmed Plaintiffs and the putative class members. Defendants removed the actions to federal court, and Plaintiffs’ motions for remand are presently before this Court in the following nine matters: 1

Case Mo: Case Name
99-cv-73314 Pearl Bence Lowy v. Hoechst, et al.
99-CV-73750 Aetna U.S. Healthcare, Inc. v. Hoechst, et al.
99-cv-73667 Jan Gabriel v. Hoechst, et al.
99-ev-73345 Larry S. Sizemore v. Hoechst, et al.
99-cv-73981 Albert Eirieh v. Hoechst, et al.
99-cv-74377 Shirlean Glover v. Hoechst, et al.
99-cv-73845 Sunshine Pharmacy of NY, Inc. v. Hoechst, et al.
99-ev-73713 D’Esposito v. Hoechst, et al.
Case No, Case Name
99-cv-73871 Galloway, Inc. v. Hoechst, et al.

Each case is addressed individually. The discussion begins with the cases where Plaintiffs plainly allege unjust enrichment or admit that Plaintiff and the class are seeking restitution or disgorgement: Gabriel, Sunshine Pharmacy, Ei-rich and Glover. Next, the Court addresses the cases where the Plaintiffs complaint specifically pleads for less than the required jurisdictional threshold amount for diversity jurisdiction: Sizemore; and those where the Plaintiffs complaint does not clearly allege unjust enrichment or seek the equitable remedies of disgorgement or restitution: Galloway, Inc. and D’Esposito. Here, the Court addresses Defendants’ arguments that aggregation is proper with regard to Plaintiffs’ claims for injunctive relief, statutory damages, and attorneys fees. Finally, the Court addresses those cases where there is no diversity of citizenship and removal, if proper, must be based on the federal question grounds Defendants assert: Lowy and Aetna U.S. Healthcare, Inc.

Plaintiffs’ motions for remand are DENIED in Gabriel, Sunshine Pharmacy, Eirieh, Glover, Sizemore, Galloway, Inc., and D’Esposito because Plaintiffs’ complaints present integrated claims which satisfy the amount-in-controversy requirement for diversity jurisdiction.' Plaintiffs’ motions for remand are GRANTED in Lowy, and Aetna U.S. Healthcare, Inc. because the Court finds no basis for federal question jurisdiction.

I. Standard of Review

“Generally, a civil case brought in state court may be removed by a defendant to federal court if it could have been brought there originally.” Gafford v. General Elec. Co., 997 F.2d 150, 155 (6th Cir. *823 1993). The burden of establishing federal jurisdiction rests “clearly upon the defendants as the removing party.” Alexander v. Electronic Data Systems Corp., 13 F.3d 940, 949 (6th Cir.1994). The court is required to “ ‘look to the complaint as it existed at the time the petition for removal was filed to determine’ the matter of federal jurisdiction raised by the defendant’s notice of removal.” Alexander, 13 F.3d at 949 (quoting Cromwell v. Equicor-Equita-ble HCA Corp., 944 F.2d 1272, 1277 (6th Cir.1991)). The federal courts strictly construe removal petitions in a manner that resolves all doubts against removal. Her Majesty The Queen v. City of Detroit, 874 F.2d 332, 339 (6th Cir.1989).

II. Analysis

A. Diversity Jurisdiction — Amount in Controversy Disputes

Defendants assert that removal is proper here because the parties are completely diverse, and the amount in controversy exceeds the $75,000 statutory minimum under 28 U.S.C. § 1332. Other than in Lowy and Aetna U.S. Healthcare, Inc., which are discussed below under federal question jurisdiction, Plaintiffs do not dispute that the parties are completely diverse but move for a remand asserting that Defendants cannot satisfy their burden of proving that the amount-in-controversy requirement under § 1332 is satisfied.

1. General Principles

a. Controlling Law.

In multidistrict litigation such as this, “the binding precedent, if any, from the Sixth Circuit should be examined and, if none exists, an evaluation of other circuit law should be undertaken in order to make a reasoned decision. This multidistrict litigation, ..., deserves to have but one interpretation of federal law.” In re Air Crash at Detroit Metro. Airport, 791 F.Supp. 1204, 1213 (E.D.Mich.1992). Although state law will dictate the nature of the claim asserted and what amounts are actually at stake, federal law will determine whether the amounts exceed the statutory minimum necessary for diversity jurisdiction under 28 U.S.C. § 1332. See 15 Moore’s Federal Practice, § 102.101 (Matthew Bender 3d ed).

b. Burden of Proof.

The defendant’s burden of proof regarding the amount in controversy varies depending on whether and how much the plaintiff seeks in damages. See Gafford v. General Elec. Co., 997 F.2d 150. If the plaintiffs complaint specifies that she is seeking an unspecified amount in damages, then the “ ‘preponderance of the evidence’ (‘more likely than not’) test” will apply, and the Defendant must show, by a preponderance standard, that the plaintiff’s allegations, if properly proved, will justify an award in excess of the jurisdictional minimum. Gafford, 997 F.2d at 158. If the plaintiffs complaint specifies that she is seeking an amount less than the amount required for diversity jurisdiction, then the defendant must show by a “substantial likelihood” or “reasonable probability” that the plaintiffs claims meet the amount-in-controversy requirement. See Gafford, 997 F.2d at 157-58; Crosby v. America Online, Inc., 967 F.Supp. 257, 261 n. 2 (N.D.Ohio 1997) 2

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Time Insurance v. Astrazeneca AB
52 F. Supp. 3d 705 (E.D. Pennsylvania, 2014)
Everett v. Verizon Wireless
Sixth Circuit, 2006
Alinsub v. T-Mobile
414 F. Supp. 2d 825 (W.D. Tennessee, 2006)
In Re Nat. Century Fin. Enterpr., Inc., Inv. Lit.
323 F. Supp. 2d 861 (S.D. Ohio, 2004)
Parrett v. Bank One, N.A.
323 F. Supp. 2d 861 (S.D. Ohio, 2004)
Virden v. Altria Group, Inc.
304 F. Supp. 2d 832 (N.D. West Virginia, 2004)
Harris v. Physicians Mutual Insurance
240 F. Supp. 2d 715 (N.D. Ohio, 2003)
In Re Tamoxifen Citrate Antitrust Litigation
222 F. Supp. 2d 326 (E.D. New York, 2002)
Perotti v. Black & Decker (U.S.) Inc.
205 F. Supp. 2d 813 (N.D. Ohio, 2002)
Gavriles v. Verizon Wireless
194 F. Supp. 2d 674 (E.D. Michigan, 2002)
In Re Ciprofloxacin Hydrochloride Antitrust Litigation
166 F. Supp. 2d 740 (E.D. New York, 2001)
In Re Ford Motor Company Citibank South Dakota)
264 F.3d 952 (Ninth Circuit, 2001)
McCauley v. Ford Motor Co.
264 F.3d 952 (Ninth Circuit, 2001)
Durant v. Servicemaster Co. Trugreen, Inc.
147 F. Supp. 2d 744 (E.D. Michigan, 2001)
In re Cardizem CD Antitrust Litigation
200 F.R.D. 326 (E.D. Michigan, 2001)
In Re Microsoft Corp. Antitrust Litigation
127 F. Supp. 2d 702 (D. Maryland, 2001)
Altman v. Bayer Corp.
125 F. Supp. 2d 666 (S.D. New York, 2000)

Cite This Page — Counsel Stack

Bluebook (online)
90 F. Supp. 2d 819, 90 F. Supp. 819, 1999 U.S. Dist. LEXIS 20698, 1999 WL 1569794, Counsel Stack Legal Research, https://law.counselstack.com/opinion/in-re-cardizem-cd-antitrust-litigation-mied-1999.